

27 February 2026

Incidence and Treatment of Breast Cancer

I am researching the incidence and treatment of breast cancer. I would greatly appreciate if you could answer the following questions

1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- | | |
|--|----|
| • Abemaciclib + Aromatase Inhibitor
(e.g. anastrozole, exemestane, letrozole) | 0 |
| • Abemaciclib + Fulvestrant | 5 |
| • Alpelisib + Fulvestrant | 0 |
| • Anthracycline (e.g. doxorubicin or epirubicin) +
Cyclophosphamide only | <5 |
| • Anthracycline (e.g. doxorubicin or epirubicin) +
Cyclophosphamide + Paclitaxel | 0 |
| • Atezolizumab | 0 |
| • Capivasertib | 0 |
| • Capecitabine as a single agent | 20 |
| • Carboplatin + Paclitaxel | 0 |
| • Elacestrant | 0 |
| • Eribulin as a single agent or in combination | <5 |
| • Everolimus + Exemestane | 0 |
| • Fulvestrant as a single agent | 9 |
| • Palbociclib + Aromatase Inhibitor
(e.g. anastrozole, exemestane, letrozole) | 0 |
| • Palbociclib + Fulvestrant | <5 |
| • Parp Inhibitors (Olaparib/Talazoparib) | 0 |
| • Pembrolizumab Monotherapy | <5 |
| • Pembrolizumab + Anthracycline (e.g. doxorubicin
or epirubicin) + Cyclophosphamide | 0 |
| • Carboplatin + Paclitaxel + Pembrolizumab | 0 |
| • Pertuzumab (Perjeta) + Trastuzumab (Herceptin) | 0 |
| • Phesgo (Pertuzumab + Trastuzumab in a single
injection) | 0 |
| • Ribociclib + Aromatase Inhibitor (e.g. anastrozole,
exemestane, letrozole) | 0 |
| • Ribociclib + Fulvestrant | <5 |

27 February 2026

• Sacituzumab Govitecan	<5
• Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent	10
• Trastuzumab deruxtecan (Enhertu)	6
• Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel	13
• Trastuzumab emtansine (Kadcyla)	<5
• Any other active systemic anti-cancer therapy	
Abemaciclib	37
Atezolizumab&Nab-Paclitaxel	<5
Capivasertib&Fulvestrant	<5
D-Phesgo	<5
EC-D	13
EC-D-Phesgo	10
EC-PC	5
EC-Weekly Paclitaxel	6
EC-weekly Paclitaxel-Phesgo	<5
Epirubicin	<5
FEC-50	<5
Palbociclib	20
Pembrolizumab&Paclitaxel	<5
Penbrolizumab&PC-EC	<5
Ribociclib	16
Tucatinib Capecitabine Trastuzumab	<5
Vinorelbine Oral	<5

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party, as the small numbers involved could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

27 February 2026

2. Does your Trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.

Studies open in breast cancer - Belfast Trust - 05/02/26	Recruited (org)
ATNEC–Axillary management in T1-3N1M0 breast cancer patients with FNA or core biopsy proven nodal metastases at presentation who convert to node negative after NEOadjuvant Chemotherapy	6
EndoNET: Randomised controlled trial evaluating effectiveness of neoadjuvant endocrine treatment in post-menopausal women	<5
FAST-Forward Boost: A randomised clinical trial testing a 1-week schedule of curative simultaneous integrated boost radiotherapy against a standard 3-week schedule in patients with early breast cancer	<5
The HER2-RADiCAL study (Response ADaptive CAre pLan) – Tailoring treatment for HER2 positive early breast cancer	<5
INAVO122 A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB IN COMBINATION WITH PHESGO VERSUS PLACEBO IN COMBINATION WITH PHESGO AFTER FIRST LINE INDUCTION THERAPY IN PARTICIPANTS WITH PIK3CA-MUTATED HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER	0
LOLIPOP: Long-term Outcomes of Lidocaine Infusions for persistent Post-Operative Pain in patients undergoing breast surgery (LOLIPOP) Trial	9
SMALL: A Phase III, randomised, multi-centre trial addressing overtreatment of small screen-detected breast cancer by comparing standard surgery versus minimally invasive vacuum-assisted excision	37

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party, as the small numbers involved could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.